Effect of CMF-chemotherapy on blood coagulation in patients with breast cancer
Archive of Oncology · 2002
DOI: 10.2298/aoo0202061p ↗Kurz gefasst
Fachartikel in der Zeitschrift Archive of Oncology, 2002. Verfasst von Dragana Petrovic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Influences of CMF (cyclophosphamide, methotrexate,5-fluorouracil) chemotherapy on blood coagulation were investigated in 30 patients receiving adjuvant chemotherapy and in 30 patients receiving chemotherapy for metastatic breast cancer. METHODS: In plasma samples of 60 patients (median age 49.5), we evaluated the following parameters 1)Markers of in vivo clotting activation thrombin-antithrombin complex (ELISA) and D-dimer (ELISA), 2) Natural anticoagulants (protein C [PC] and antithrombin III [AT III] by chromogenic methods). The coagulation studies were performed at the beginning and at the end of the first cycle of CMF protocol. RESULTS: Before CMF therapy, significant difference was observed between patients with early stage and patients with metastatic breast cancer in the PC (p
Zitieren
APA
Petrovic, D. (2002). Effect of CMF-chemotherapy on blood coagulation in patients with breast cancer. Archive of Oncology. https://doi.org/10.2298/aoo0202061p
Vancouver
Petrovic D. Effect of CMF-chemotherapy on blood coagulation in patients with breast cancer. Archive of Oncology. 2002. doi:10.2298/aoo0202061p
BibTeX
@article{Petrovic2002,
author = {Petrovic, Dragana},
title = {Effect of CMF-chemotherapy on blood coagulation in patients with breast cancer},
journal = {Archive of Oncology},
year = {2002},
doi = {10.2298/aoo0202061p}
}
EUVIMED